Pier Capital’s Sage Therapeutics SAGE Stock Holding History

Pier Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-115,506	Closed	-$5.9M	–	122
2016 Q4	$5.9M	Sell	115,506 -6,233	-5%	-$294K	1.07%	25
2016 Q3	$5.61M	Buy	+121,739	New	+$4.96M	0.99%	56

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Pier Capital's SAGE Position: Q1 2017 in Review

Pier Capital sold out of Sage Therapeutics (SAGE) in Q1 2017, closing a stake of 115,506 shares — an estimated $5.9M sold.

Pier Capital first reported a position in SAGE in Q3 2016 and held it in 2 quarters. The position peaked at $5.9M in Q4 2016. 190 funds tracked by Wall St. Rank hold SAGE as of Q1 2017.

Pier Capital reported no remaining Sage Therapeutics position as of Q1 2017 after selling out during the quarter.
Pier Capital sold 115,506 Sage Therapeutics shares in Q1 2017, an estimated $5.9M.
Pier Capital first reported a position in Sage Therapeutics in Q3 2016 and held it in 2 quarters.
Pier Capital's Sage Therapeutics position peaked at $5.9M in Q4 2016.
190 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2017.

Based on Pier Capital's 13F filing for Q1 2017, filed 10 May 2017.